Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Description What this blend is No study has tested this combination Structure and identity both components Where the evidence stands Component 1 the CJC-1295 evidence Component 2 the ipamorelin evidence The synergy rationale, and its status What a blend does to your data Limitations of the literature Regulatory and anti-doping status What we dont know References What this blend is This vial contains two distinct peptides, co-lyophilised: CJC-1295 without DAC a 29-residue GHRH analogue acting at the GHRH receptor and ipamorelin a pentapeptide agonist at the ghrelin receptor, a completely different receptor
SURMOUNT-1 Trial (Obesity Without Diabetes) Jastreboff, A
This peptide blend is discussed as a combination of a synthetic gastric-derived peptide fragment and a thymosin beta peptide analogue
3 Johns Hopkins Drug Discovery, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA Correspondence: Soo Kyung Bae, College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, 14662, Republic of Korea, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are peptide-derived analogs that were initially investigated to treat type 2 diabetes
10.1210/en.2013-1096 65
US$ 27.91
US$ 29.35
US$ 22.72
